As for mutations in the MEK (MAPK) genes, there are less data, but MEK inhibitors are also used in melanoma therapy, together with BRAF inhibitors to combat fast resistance to BRAFi therapy and decrease the cutaneous side effects related to paradoxical MAPK pathway activation with BRAF inhibitor monotherapy. Here, MAP2K7 is linked to melanoma.